HomeCompareSODE vs ABBV

SODE vs ABBV: Dividend Comparison 2026

SODE yields 16963.53% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SODE wins by $10246377104631222272.00M in total portfolio value
10 years
SODE
SODE
● Live price
16963.53%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10246377104631222272.00M
Annual income
$10,128,918,546,596,361,000,000,000.00
Full SODE calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SODE vs ABBV

📍 SODE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSODEABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SODE + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SODE pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SODE
Annual income on $10K today (after 15% tax)
$1,441,899.92/yr
After 10yr DRIP, annual income (after tax)
$8,609,580,764,606,907,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SODE beats the other by $8,609,580,764,606,907,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SODE + ABBV for your $10,000?

SODE: 50%ABBV: 50%
100% ABBV50/50100% SODE
Portfolio after 10yr
$5123188552315611136.00M
Annual income
$5,064,459,273,298,181,000,000,000.00/yr
Blended yield
98.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SODE
No analyst data
Altman Z
13.0
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SODE buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSODEABBV
Forward yield16963.53%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$10246377104631222272.00M$102.3K
Annual income after 10y$10,128,918,546,596,361,000,000,000.00$24,771.77
Total dividends collected$10238615175381477376.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SODE vs ABBV ($10,000, DRIP)

YearSODE PortfolioSODE Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,707,053$1,696,352.84$11,550$430.00+$1.70MSODE
2$272,458,690$270,632,143.73$13,472$627.96+$272.45MSODE
3$40,660,652,416$40,369,121,617.58$15,906$926.08+$40660.64MSODE
4$5,673,906,260,310$5,630,399,362,224.48$19,071$1,382.55+$5673906.24MSODE
5$740,353,678,442,688$734,282,598,744,156.80$23,302$2,095.81+$740353678.42MSODE
6$90,336,188,725,930,750$89,544,010,289,997,060.00$29,150$3,237.93+$90336188725.90MSODE
7$10,307,824,588,220,858,000$10,211,164,866,284,112,000.00$37,536$5,121.41+$10307824588220.82MSODE
8$1,099,951,357,331,648,700,000$1,088,921,985,022,252,500,000.00$50,079$8,338.38+$1099951357331648.63MSODE
9$109,774,353,303,607,160,000,000$108,597,405,351,262,300,000,000.00$69,753$14,065.80+$109774353303607152.00MSODE
10$10,246,377,104,631,222,000,000,000$10,128,918,546,596,361,000,000,000.00$102,337$24,771.77+$10246377104631222272.00MSODE

SODE vs ABBV: Complete Analysis 2026

SODEStock

Social Detention, Inc. provides infrastructure and security solutions. The company is based in Alamo, California.

Full SODE Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SODE vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SODE vs SCHDSODE vs JEPISODE vs OSODE vs KOSODE vs MAINSODE vs JNJSODE vs MRKSODE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.